SIONNA THERAPEUTICS, INC. Operating Expenses
SIONNA THERAPEUTICS, INC. (SION) reported Operating Expenses of $32.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $32.47M, a 48.22% increase year-over-year.
- SIONNA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $29.60M, a 50.56% increase year-over-year.
- SIONNA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $23.61M, a 30.22% increase year-over-year.
- SIONNA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $23.80M, a 14.93% decline year-over-year.
- SIONNA THERAPEUTICS, INC. operating expenses for fiscal 2025 was $88.98M, a 26.12% increase from fiscal 2024.
- SIONNA THERAPEUTICS, INC. operating expenses for fiscal 2024 was $70.56M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.47M 10-Q · filed 2026-08-06 | $62.07M 10-Q · filed 2026-08-06 | $85.68M derived: sum of 3 quarters · filed 2026-08-06 | $109.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $29.60M 10-Q · filed 2026-05-12 | $53.21M derived: sum of 2 quarters · filed 2026-05-12 | $77.02M derived: sum of 3 quarters · filed 2026-05-12 | $98.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $47.42M derived: sum of 2 quarters · filed 2026-03-02 | $69.32M derived: sum of 3 quarters · filed 2026-08-06 | $88.98M 10-K · filed 2026-03-02 |
| 2025-09-30 | $23.80M 10-Q · filed 2025-11-05 | $45.71M derived: sum of 2 quarters · filed 2026-08-06 | $65.37M 10-Q · filed 2025-11-05 | $83.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.91M 10-Q · filed 2026-08-06 | $41.56M 10-Q · filed 2026-08-06 | $59.70M derived: sum of 3 quarters · filed 2026-08-06 | $87.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $19.66M 10-Q · filed 2026-05-12 | $37.79M derived: sum of 2 quarters · filed 2026-05-12 | $65.78M derived: sum of 3 quarters · filed 2026-05-12 | $77.07M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $18.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $46.12M derived: sum of 2 quarters · filed 2026-03-02 | $57.41M derived: sum of 3 quarters · filed 2026-03-02 | $70.56M 10-K · filed 2026-03-02 |
| 2024-09-30 | $27.98M 10-Q · filed 2025-11-05 | $39.28M derived: sum of 2 quarters · filed 2025-11-05 | $52.42M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $11.29M 10-Q · filed 2025-08-11 | $24.44M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $13.15M 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |